Genetically Modified Organisms Sample Clauses

Genetically Modified Organisms. If a Centre involves the use of gene technology (as defined in the Gene Technology Act 2000), then before the proposed research commences, the Administering Organisation must ensure that the research has been approved in writing by the relevant Biosafety and/or Ethics Committees (or equivalent) of the Administering Organisation. The Administering Organisation must retain all certificates relating to the above and will provide evidence to the Scheme Coordinator if required to do so. The Administering Organisation must be accredited with the Office of the Gene Technology Regulator.

Genetically Modified Organisms. You are not insured for liability in connection with genetically modified engineered organisms or material, transgenic seeds or any other products of a similar nature.

Genetically Modified Organisms. The Seller must advise the Company in writing if they have grown any genetically modified (GM) crops or if any goods sold to the Company may have been contaminated. The Seller should take adequate precautions to avoid any contact with or contamination by genetically modified organisms. The Company reserves the right to renegotiate any contract if GM contamination is declared or proven, and to claim any consequential costs and damages.

Genetically Modified Organisms. If a Project involves the use of gene technology (as defined in the Gene Technology Act 2000), then before the proposed research commences, the Administering Organisation must ensure that the research has been approved in writing by the relevant Biosafety and/or Ethics Committees (or equivalent) of the Administering Organisation. The Administering Organisation must retain all certificates relating to the above and will provide evidence to the ARC if required to do so. The Administering Organisation must be accredited with the Office of the Gene Technology Regulator. Ionising radiation: If a Project involves the use of ionising radiation, the Administering Organisation must ensure that any personnel performing procedures involving ionising radiation are appropriately trained and hold a relevant current licence from the appropriate State authority. The Administering Organisation must retain all such licences and provide them to the ARC if required to do so. Social science data sets: Any digital data arising from a Project involving research relating to the social sciences must be lodged with the Australian Data Archive (ADA) or another equivalent repository for secondary use by other investigators. This must normally be done within two years of the conclusion of any fieldwork relating to the research. If a CI is not intending to do so within the two-year period, they must include the reasons in the Final Report. Australian Antarctic Division: All research projects conducted in the Antarctic, the Subantarctic and the Southern Ocean must comply with all relevant international obligations and national and state legislative requirements regardless of the provider of logistics support. CIs are required to inform the Australian Antarctic Division (AAD) of any Australian traveling to the Antarctic, the Subantarctic or Southern Ocean as part of the project. The AAD will provide advice on the necessary permits, work health and safety requirements, and other steps that need to be taken prior to travel. Further information on the conditions are provided on the AAD website. Schedule A also provides further information regarding travel to the Antarctic, the Subantarctic and the Southern Ocean.

Genetically Modified Organisms. (a) Schedule 3.21 sets forth complete details of the procedures performed by or on behalf of Seller or the Company to minimize the possibility of unapproved GMOs existing in any Transferred Germplasm and of assessments made by or on behalf of Seller or the Company as to the effectiveness of such procedures and steps taken to implement such procedures. Seller and the Company have, since the introduction of such procedures, operated in accordance with the terms of such procedures and, other than with respect to ongoing improvements to them, has not deviated from such procedures or failed to implement such procedures in connection with the use by Seller or the Company of any Transferred Germplasm. (b) No unapproved GMOs, including any StarLink presence, exist or have existed in any of the seed currently being sold, or which has been sold, commercially by Seller or the Company; provided that the representation in this paragraph shall not be applicable to any seed purchased by the Seller or the Company from the Buyer or its Affiliates.

Genetically Modified Organisms. (a) The Company and its Subsidiaries have developed, implemented and are complying globally with quality management practices and procedures intended to prevent the unintended presence of regulated biotech traits in their research and commercial seed materials. (b) Except as set forth on Schedule 5.14(b), since December 30, 1999, neither the Company nor any of its Subsidiaries has knowingly delivered seed to a final customer into a country containing a regulated trait without all appropriate regulatory permits and approvals, or delivered seed that has been produced in non-compliance with the quality management practices described in Section 5.14(a). (c) To the Knowledge of the Company, in the United States,there are no market claims or reports of the presence of unintended regulated traits in the products of the Company or any of its Subsidiaries or in materials directly derived from such products.

Genetically Modified Organisms. Working with genetically modified microorganisms (GMM) and organisms (GMO) requires specific facilities and procedures to ensure that both you, your coworkers, and the environment are safe.

Genetically Modified Organisms. (a) Seller’s quality assurance and stewardship manuals, including manuals for each cotton elite event, that relate to the Stoneville Package are attached hereto as Schedule 5.16(a) (the “Seller Manuals”). Each of the Seller, the Company and DSTC has developed, implemented and is complying globally with quality assurance and stewardship practices and procedures with respect to the Business, including those practices and procedures described in the Seller Manuals, which are intended, among other things, to prevent the unlawful adventitious presence of regulated and deregulated transformation events in its research and commercial cotton seed materials, including the testing of foundation commercial seed materials used in the Business. (b) Neither the Seller in connection with the Business, nor the Company or DSTC has handled seed or any other biological material, or delivered seed or any other biological material to any third-party, containing a regulated transformation event without all appropriate regulatory permits and approvals being in place, or handled or delivered seed or any other biological material that has not been handled and used in all respects in compliance with the Seller Manuals. The Seller in connection with the Business, the Company and DSTC have each taken commercially reasonable efforts to ensure that their respective third-party contractors have complied with Laws applicable to unintended regulated or deregulated transformation events and the procedures set forth in the Seller Manuals. The Seller with respect to the Business, the Company and DSTC have implemented reasonable procedures designed to audit such compliance by third-party contractors, and, to the Knowledge of the Seller, no third-party contractor has violated any such Laws or procedures. (c) To the Knowledge of the Seller there are no market claims or reports of the presence of unintended regulated transformation events or unlawful levels of unintended deregulated transformation events in the seeds or any other biological material of the Business or of the Company or DSTC or in materials derived from such seeds or biological material. (d) The Company and DSTC (i) discontinued sales of products containing any bromoxynil tolerant cotton transformation event prior to December 31, 2004, (ii) have notified their licensees of such discontinuation and (iii) have made commercially reasonable efforts to notify appropriate licensees, distributors, growers and regulators and to direct ap...

Genetically Modified Organisms. (a) The Company and its Subsidiaries have developed, implemented and are complying globally with quality management practices and procedures intended to prevent the unintended presence of regulated biotech traits in their research and commercial seed materials. (b) Except as set forth on Schedule 5.14(b), since December 30, 1999, neither the Company nor any of its Subsidiaries has knowingly delivered seed to a final customer into a country containing a regulated trait without all appropriate regulatory permits and approvals, or delivered seed that has been produced in non-compliance with the quality management practices described in Section 5.14(a). (c) To the Knowledge of the Company, in the United States, there are no market claims or reports of the presence of unintended regulated traits in the products of the Company or any of its Subsidiaries or in materials directly derived from such products. (d) The Company and its Subsidiaries (i) discontinued sales of products containing the bromoxynil tolerant cotton event prior to December 31, 2004, (ii) have notified their licensees of such discontinuation and (iii) have made commercially reasonable efforts to notify appropriate distributors, growers and regulators and to recover all materials containing bromoxynil tolerant cotton seed in an effort to prevent any additional plantings. The Company has in its possession all methods and materials related to all bromoxynil tolerant cotton events.